Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 52
HOS-112183 · Präparat HOS-093615
The mechanism of interaction is decreased
solubility of atazanavir as intra-gastric pH
increases with H2-blockers.
Proton pump inhibitors
Omeprazole 40 mg once daily Atazanavir (am): 2 hr after omeprazole Co-administration of
(atazanavir 400 mg once daily Atazanavir AUC: ↓61% (↓65% ↓55%) REYATAZ with ritonavir and
with ritonavir 100 mg once Atazanavir Cmax: ↓66% (↓62% ↓49%) proton pump inhibitors is not
daily) Atazanavir Cmin: ↓65% (↓71% ↓59%) recommended. If the
Omeprazole 20 mg once daily Atazanavir (am): 1 hr after omeprazole combination is judged
(atazanavir 400 mg once daily Atazanavir AUC: ↓30% (↓43% ↓14%)* unavoidable, close clinical
with ritonavir 100 mg once Atazanavir Cmax: ↓31% (↓42% ↓17%)* monitoring is recommended in
daily) Atazanavir Cmin: ↓31% (↓46% ↓12%)* combination with an increase
in the dose of REYATAZ to
*When compared to atazanavir 300 mg 400 mg with 100 mg of
once daily with ritonavir 100 mg once ritonavir; doses of proton
daily. pump inhibitors comparable to
omeprazole 20 mg should not
The decrease in AUC, Cmax, and Cmin was be exceeded (see section 4.4).
not mitigated when an increased dose of
REYATAZ/ritonavir (400/100 mg once
daily) was temporally separated from
omeprazole by 12 hours. Although not
studied, similar results are expected with
other proton pump inhibitors. This decrease
in atazanavir exposure might negatively
impact the efficacy of atazanavir. The
mechanism of interaction is decreased
solubility of atazanavir as intra-gastric pH
increases with proton pump inhibitors.
Antacids
Antacids and medicinal
Reduced plasma concentrations of REYATAZ should be
products containing buffers
atazanavir may be the consequence of administered 2 hours before or
increased gastric pH if antacids, including 1 hour after antacids or
buffered medicinal products, are buffered medicinal products.
administered with REYATAZ.
ALPHA 1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Potential for increased alfuzosin Co-administration of alfuzosin
concentrations which can result in with REYATAZ is
hypotension. The mechanism of interaction contraindicated (see
is CYP3A4 inhibition by REYATAZ section 4.3)
and/or ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 80039b3c9941b0ea6e88b75dc521d347e84e1e55a05e032b6e4e6af5cea420e4 · Zeichen 36783–40246 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 12
HOS-112769 · Präparat HOS-093755
In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on
the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the
pharmacokinetics of bortezomib based on data from 17 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage e61ca7f129845087c7db6cc31da699dbb91f3cd7f3efe9e76336710b53329e12 · Zeichen 724–986 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 3.5 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 43–44
HOS-112802 · Präparat HOS-093755
43
In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on
the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the
pharmacokinetics of bortezomib based on data from 17 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 058a40c98957e063cd239e2202dd15e7f8c6454ebb88a4642039aa8ae9f5c7cb · Zeichen 774–1040 im Abschnitt
Wechselwirkungen · Xyrem
Xyrem 500 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 7
HOS-113664 · Präparat HOS-093953
Omeprazole
The co-administration of omeprazole has no clinically significant effect on the pharmacokinetics of
sodium oxybate. The dose of sodium oxybate therefore does not require adjustment when given
concomitantly with proton pump inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-12T16:47:00Z · SHA-256 458b7a20ee31b89a8296f6c62f1482472a82c1e2139396dca882dd3f5b361fd3 · Passage 7d5159f6fd6a3e588f3f1594e394d0a9b254d6df75aaebca8a6bbcfcfd9b2ad1 · Zeichen 2669–2914 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113863 · Präparat HOS-093985
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
7
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined with
ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin
II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG
CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 6fe50dfb92b6505d72aae832687fd6d506058eea7817db26b92c97470c5cf7b0 · Zeichen 3733–4843 im Abschnitt
Wechselwirkungen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113899 · Präparat HOS-093993
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
7
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined with
ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin
II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG
CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage fa836be3022093cccc5a3b6212d038585510c2a7d953cbad3447bdbe000be9a4 · Zeichen 3735–4845 im Abschnitt
Wechselwirkungen · Tarceva
Tarceva 25 mg film-coated tablets Tarceva 100 mg film-coated tablets Tarceva 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-114482 · Präparat HOS-094097
Erlotinib and medicinal products altering pH
Erlotinib is characterised by a decrease in solubility at pH above 5. Medicinal products that alter the
pH of the upper Gastro-Intestinal (GI) tract may alter the solubility of erlotinib and hence its
bioavailability. Co-administration of erlotinib with omeprazole, a proton pump inhibitor (PPI),
decreased the erlotinib exposure [AUC] and maximum concentration [Cmax] by 46% and 61%,
respectively. There was no change to Tmax or half-life. Concomitant administration of Tarceva with
300 mg ranitidine, an H2-receptor antagonist, decreased erlotinib exposure [AUC] and maximum
concentrations [Cmax] by 33% and 54%, respectively. Increasing the dose of Tarceva when co-
administered with such agents is not likely to compensate for this loss of exposure. However, when
Tarceva was dosed in a staggered manner 2 hours before or 10 hours after ranitidine 150 mg b.i.d.,
erlotinib exposure [AUC] and maximum concentrations [Cmax] decreased only by 15% and 17%,
respectively. The effect of antacids on the absorption of erlotinib has not been investigated but
7
absorption may be impaired, leading to lower plasma levels. In summary, the combination of erlotinib
with proton pump inhibitors should be avoided. If the use of antacids is considered necessary during
treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of
Tarceva. If the use of ranitidine is considered, it should be used in a staggered manner; i.e. Tarceva
must be taken at least 2 hours before or 10 hours after ranitidine dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T14:10:00Z · SHA-256 4f9c738a5861ce6d74c31277709e30968e275c29015450902926409dd5330a31 · Passage 264b6f35fedea9650cddcad1829da970f9422aa822dfd63550bcdd77df146e58 · Zeichen 6109–7747 im Abschnitt
Wechselwirkungen · Neupro
Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 6
HOS-114657 · Präparat HOS-094135
Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the
pharmacokinetics and metabolism of rotigotine in healthy volunteers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage c4930d248d604ac14f6ca35d86c5e35d68cc5a81a607cb2b81af2f44e02217cb · Zeichen 874–1042 im Abschnitt
Wechselwirkungen · Neupro
Neupro 2 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 20
HOS-114683 · Präparat HOS-094135
Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the
pharmacokinetics and metabolism of rotigotine in healthy volunteers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage c4930d248d604ac14f6ca35d86c5e35d68cc5a81a607cb2b81af2f44e02217cb · Zeichen 876–1044 im Abschnitt
Wechselwirkungen · Neupro
Neupro 4 mg/24 h transdermal patch Neupro 6 mg/24 h transdermal patch Neupro 8 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 38
HOS-114719 · Präparat HOS-094135
Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the
pharmacokinetics and metabolism of rotigotine in healthy volunteers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage c4930d248d604ac14f6ca35d86c5e35d68cc5a81a607cb2b81af2f44e02217cb · Zeichen 819–987 im Abschnitt
Wechselwirkungen · Neupro
Neupro 2 mg/24 h 4 mg/24 h 6 mg/24 h 8 mg/24 h Transdermal patch · Abschnitt 4.5 · PDF-Seite 53
HOS-114743 · Präparat HOS-094135
Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the
pharmacokinetics and metabolism of rotigotine in healthy volunteers.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage c4930d248d604ac14f6ca35d86c5e35d68cc5a81a607cb2b81af2f44e02217cb · Zeichen 819–987 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-114841 · Präparat HOS-094169
Antacids
aluminium- and Tipranavir Cmax ↓ 25% Dosing of Aptivus, co-
magnesium-based antacid Tipranavir AUC ↓ 27% administered with low dose
QD ritonavir, with antacids should be
Mechanism unknown separated by at least a two hours
time interval.
Proton pump inhibitors (PPIs)
Omeprazole 40 mg QD Omeprazole Cmax ↓ 73% The combined use of Aptivus, co-
Omeprazole AUC ↓ 70% administered with low dose
ritonavir, with either omeprazole
Similar effects were observed for or esomeprazole is not
the S-enantiomer, esomeprazole. recommended (see section 4.4). If
unavoidable, upward dose
Induction of CYP 2C19 by adjustments for either
tipranavir/r omeprazole or esomeprazole may
be considered based on clinical
Tipranavir ↔ response to therapy. There are no
data available indicating that
omeprazole or esomeprazole dose
adjustments will overcome the
observed pharmacokinetic
interaction. Recommendations
for maximal doses of omeprazole
or esomeprazole are found in the
corresponding product
information. No tipranavir with
ritonavir dose adjustment is
required.
Lansoprazole Based on the metabolic profiles The combined use of Aptivus, co-
Pantoprazole of tipranavir/r and the proton administered with low dose
Rabeprazole pump inhibitors, an interaction ritonavir, with proton pump
No interaction study can be expected. As a result of inhibitors is not recommended
performed CYP3A4 inhibition and (see section 4.4). If the co-
CYP2C19 induction by administration is judged
tipranavir/r, lansoprazole and unavoidable, this should be done
pantoprazole plasma under close clinical monitoring.
concentrations are difficult to
predict. Rabeprazole plasma
concentrations might decrease as
a result of induction of CYP2C19
by tipranavir/r.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage c99aa431c7e3f77cb519d4da2aced0a374d801c9c352b5d32534ed58e4e72798 · Zeichen 45182–48575 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-115308 · Präparat HOS-094267
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. HIV protease inhibitors,
antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins, oral
contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section for
antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is recommended. A
dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage d0f42d8f593222b754dd51125c16cac4738a18df13892197979077dd910686ea · Zeichen 1429–1956 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg hard capsules · Abschnitt 4.5 · PDF-Seite 16
HOS-115381 · Präparat HOS-094267
At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: for
example, CYP2C19, CYP2D6 and CYP3A4. As a result, pharmacokinetic interactions of metabolic
origin with other medicines may be expected. These interactions may result in increased systemic
levels of these active substances that may lead to enhanced pharmacological effects and to an increase
in adverse reactions.
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. HIV protease inhibitors,
antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins, oral
contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section for
antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is recommended. A
dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) lead (HOS-085592) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage 461e95e0afe38eed84d94f312102213f5ddd1a0784f12f64d24f311bc3bbb136 · Zeichen 1019–1957 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 27
HOS-115415 · Präparat HOS-094267
At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: for
example, CYP2C19, CYP2D6 and CYP3A4. As a result, pharmacokinetic interactions of metabolic
origin with other medicines may be expected. These interactions may result in increased systemic
levels of these active substances that may lead to enhanced pharmacological effects and to an increase
in adverse reactions.
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. several HIV protease
inhibitors, antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins,
oral contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section
for antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is
recommended. A dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) lead (HOS-085592) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage 890a2b068107a3872634a445054ed75c39b3905a5e8af1130059232a7739a5f2 · Zeichen 1018–1964 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 38
HOS-115450 · Präparat HOS-094267
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. several HIV protease
inhibitors, antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins,
oral contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section
for antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is
recommended. A dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage b84435ca1a4cdf73091bf84be97bf4ecc4ba97440a16fe3b236aaf5fc17b9d87 · Zeichen 1430–1965 im Abschnitt
Wechselwirkungen · Nexavar
Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-115756 · Präparat HOS-094353
Concomitant administration of sorafenib and midazolam, dextromethorphan or omeprazole, which are
substrates for cytochromes CYP3A4, CYP2D6 and CYP2C19 respectively, did not alter the exposure
of these agents. This indicates that sorafenib is neither an inhibitor nor an inducer of these cytochrome
P450 isoenzymes. Therefore, clinical pharmacokinetic interactions of sorafenib with substrates of
these enzymes are unlikely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dextromethorphan (HOS-109265) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage b148ecdbd1e4d662338f80e06947998c6b218ec2c4abb518bb78c309ba5d1551 · Zeichen 1698–2121 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 23–24
HOS-116425 · Präparat HOS-094447
23
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil boosted PREZISTA may increase plasma co-administered with boosted
Tadalafil concentrations of sildenafil or tadalafil. PREZISTA has not been
(CYP3A inhibition) established. There is an increased
potential for sildenafil-associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
boosted PREZISTA and sildenafil
when used for the treatment of
pulmonary arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with boosted
PREZISTA is not recommended.
PROTON PUMP INHIBITORS
Omeprazole # Boosted PREZISTA can be
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ co-administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with boosted co-administering boosted
Estazolam PREZISTA may cause a large increase in PREZISTA with these
Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower
Midazolam (parenteral) dose of the sedatives/hypnotics
Zolpidem should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9634d5188deeb063704d3dec6fa9fde3f4c10970d03131c50c223d1e001e36d7 · Zeichen 72803–75985 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 65–66
HOS-116532 · Präparat HOS-094447
65
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil darunavir co-administered with low dose co-administered with PREZISTA
Tadalafil ritonavir may increase plasma and low dose ritonavir has not
concentrations of sildenafil or tadalafil. been established. There is an
(CYP3A inhibition) increased potential for
sildenafil-associated adverse
events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
PREZISTA with low dose
ritonavir and sildenafil when used
for the treatment of pulmonary
arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with PREZISTA and
low dose ritonavir is not
recommended.
PROTON PUMP INHIBITORS
Omeprazole # PREZISTA co-administered with
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with proton pump
inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with co-administering PREZISTA with
Estazolam PREZISTA/ritonavir may cause a large these sedatives/hypnotics and a
Flurazepam increase in the concentration of these lower dose of the
Midazolam (parenteral) medicines. sedatives/hypnotics should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) ritonavir (HOS-084521) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d55e033062b465321f1e7d6496fca1203bde2ceee842c6b87a58cc57f689d470 · Zeichen 63956–67534 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 105–106
HOS-116621 · Präparat HOS-094447
105
PROTON PUMP INHIBITORS
Omeprazole # Boosted PREZISTA can be
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ co-administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with boosted co-administering boosted
Estazolam PREZISTA may cause a large increase in PREZISTA with these
Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower
Midazolam (parenteral) dose of the sedatives/hypnotics
Zolpidem should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage a73d9af50672fdd14c65bde9d86094db034ee45f6e6d86b95e800c8a40b7c035 · Zeichen 74475–75820 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.